Abstract: The invention provides immunostimulatory compositions comprising an aggregate immunostimulatory amount ofa) a compound associated with the synthesis of polyamines,b) a nucleobase source,c) omega-3 polyunsaturated fatty acids, andd) omega-6 polyunsaturated fatty acidsthe use of such compositions and their manufacture.

Abstract: An extemporaneous kit of pharmaceutical substance-containing fat emulsion which consists of a fat emulsion and (a) a pharmaceutical substance composition containing pharmaceutical substance and at least one solvent selected from the group consisting of water, liquid polyalkylene glycols, liquid alkylethanolamines, and liquid polyhydric alcohols, or (b) a pharmaceutical substance composition containing pharmaceutical substance and saccharides and/or 30 amino acids as an excipient, and a process for preparation of a pharmaceutical substance-containing fat emulsion therefrom.

Abstract: In one embodiment this invention provides an improved process for the production of fatty acid calcium salt. An important feature of the process is the utilization of a residual effluent byproduct stream from a sodium bicarbonate manufacturing plant as the aqueous medium of the fatty acid calcium salt-forming reaction process.A product of the invention process is a fatty acid salt dietary supplement composition which contains one or more additional biologically active nutrient or medicament ingredients.

Abstract: The present invention relates to an immunosuppressive agent which comprises at least one compound selected from the compounds of formula ##STR1## wherein R represents a hydrogen atom or an acyl, Y represents carbonyl or hydroxymethylene and represents a single bond or a double bond and their lactones, in an effective amount and a pharmaceutically acceptable carrier; a method of prophylaxis and therapy for suppressing rejection or autoimmune diseases which comprises administering the above-mentioned compound or its lactone in an effective amount; and a novel compound of formula ##STR2## or its lactone.

Abstract: Described is a stick shave formulation and article employing said formulation. The stick shave formulation contains a triethanolamine stearate soap formed in situ with from 1-10% of a nonionic wetting agent; from 1-15% of a silicone copolymer; from 0.1-1% of a polyoxyethylene polymer slip agent; from 1-30% of a synthetic detergent; from 2-10% of a whitening agent; and 5-20% of emollient moisturizers and hair lubricants.

Abstract: The present invention discloses a topical antimicrobial and anti-parasite pharmaceutical composition and methods of using the same. The topical antimicrobial pharmaceutical composition includes a safe and effective amount of an ethoxylated or propoxylated glycerol fatty acid ester and a pharmaceutically acceptable carrier. Also disclosed is a topical antimicrobial pharmaceutical composition including a safe and effective amount of a tertiary mixture including, a glycerol fatty acid ester, a binary mixture of fatty acids including a first fatty acid antimicrobial agent selected from C.sub.6 to C.sub.18 fatty acids, and a second fatty acid antimicrobial agent selected from C.sub.6 to C.sub.18 fatty acids, and a pharmaceutically acceptable carrier. Further disclosed is a topical antimicrobial pharmaceutical composition including a safe and effective amount of an ethoxylated or propoxylated glycerol fatty acid ester, a binary fatty acid mixture including, a first fatty acid antimicrobial agent selected from C.

Abstract: Novel aluminum and aluminum-zirconium salts are produced by reacting aluminum or aluminum-zirconium halohydrate with an anionic lipophilic component. These salts are useful in antiperspirant compositions or as rheological additives. Also disclosed is a novel process of producing oil-in-water emulsions whereby the novel aluminum or aluminum-zirconium salt functions as a surfactant upon forming.

Abstract: A peroxyacid antimicrobial concentrate and use composition is provided comprising a C.sub.1 to C.sub.4 peroxycarboxylic acid, and a C.sub.6 to C.sub.18 peroxyacid. The combination of these acids produces a synergistic effect, providing a much more potent biocide than can be obtained by using these components separately. Other components can be added to the composition such as hydrotrope coupling agents, stabilizers, etc. An effective antimicrobial use solution is formed at low concentrations when the concentrate composition is diluted with water to a pH in the range of about 2 to 8. Sanitizing of substantially fixed, "in-place" processing lines in dairies, breweries, and other food processing operations is one utility of the composition.

Abstract: Treatment or prevention of memory loss with a medicament consisting of an n-6 essential fatty acid selected from GLA, DGLA, AA, adrenic acid and the 22:5 n-6 acid and an n-3 essential fatty acid selected from the 18:4 n-3 and 20:4 n-3 acids, EPA, the 22:5 n-3 acid and DHA.

Abstract: Parenteral nutritional compositions are described that contain a source of gamma-linolenic acid. A method of parenterally administering these compositions is also disclosed.

Abstract: Particles having an average diameter of less than about 12 microns comprising fatty acid cores encapsulated with human serum albumin and methods for their preparation are disclosed. These materials are useful as contrast agents in ultrasonic imaging, having scattering intensities that are equivalent to or greater than those obtain from dispersed microbubbles but being much more stable, both in storage and when used in vivo, than are contrast agents based on dispersed microbubbles.

Abstract: Composition containing nervonic acid (cis-tetracos-15-enoic acid) in a physiologically acceptable form are useful in the treatment of demyelinating disease, such as multiple sclerosis. Additional long chain fatty acids of chain length C16 to C26, especially erucic acid, or their esters, may be included in such compositions.

Abstract: Quinone derivatives of the general formula: ##STR1## (wherein R.sup.1 and R.sup.2 are the same or different, and independently are a hydrogen atom or a methyl or methoxy group, or R.sup.1 and R.sup.2 combine with each other to represent --CH.dbd.CH--CH.dbd.CH--R.sup.3 is a hydrogen atom or a methyl group; R.sup.4 is an aliphatic, aromatic or heterocyclic group which may be substituted; R.sup.5 is a methyl or methoxy group, a hydroxymethyl group which may be substituted or a carboxyl group which may be esterified or amidated; Z is a group represented by --C.dbd.C--, --CH.dbd.CH--, ##STR2## n is an integer of 0 to 10; m is an integer of 0 to 3; k is an integer of 0 to 5, provided, however, that in the case of m being 2 or 3, Z and k can vary arbitrarily within the bracketed repeating units) are novel compounds, possess metabolism ameliorating action for polyunsaturated fatty acids, particularly production inhibitory activity of lipid peroxides (antioxidant activity), thromboxane A.sub.

Abstract: Described is a stick shave formulation and article employing said formulation. The stick shave formulation contains a triethanolamine stearate soap formed in situ with from 1-10% of a nonionic wetting agent; from 1-15% of a silicone copolymer; from 0.1-1% of a polyoxyethylene polymer slip agent; from 1-30% of a synthetic detergent; from 2-10% of a whitening agent; and 5-20% of emollient moisturizers and hair lubricants.

Abstract: A non-aqueous pharmaceutical liquid suspension having improved bioavailability for oral administration comprises an active ingredient suspended in an edible, non-aqueous carrier vehicle such as an oil, wherein the active ingredient is in the form of controlled release particles containing the active ingredient and optionally an excipient in intimate admixture with at least one non-toxic polymer, the particles being coated with, distributed through or adsorbed onto said polymer, and the particles further having an average size in the range 0.1 to 150 microns and a predetermined release of active ingredient.

Abstract: By ultrafiltration of an aqueous solution wherein there have been formerly dissolved alfa-cyclodextrin and a raw lipidic mixture, the latter characterized in that it contains monosialoganglioside (GMl) either as the sole ganglioside or otherwise in a prevailing quantity over the other associated gangliosides, and after the removal of cyclodextrin at the end of the process, it is obtained GMl with a titer of at least 95%. The present invention concerns also the intermediate complex that it is being formed between the hereabove said monosialoganglioside and alfa-cyclodextrin.

Abstract: A method and composition for the treatment of a patient with AIDS. The composition comprises an AIDS-symptom alleviating effective amount of an aliphatic carboxylic acid having an odd number of carbon atoms and containing at least 5 and not more than 10 carbon atoms. The composition may be administered in a pharmaceutically acceptable oily carrier and is administered orally and/or by intramuscular injection.

Abstract: A method of inhibiting parasitic activity is disclosed in which the biosynthesis of the glycosyl phosphatidylinositol (GPI) anchor of said parasite is inhibited by incorporating into said GPI anchor an oxy-substituted fatty acid analog in place of myristate. The inhibitory compounds ar C.sub.13 and C.sub.14 fatty acids or alkyl esters thereof in which a methylene group normally in carbon position 4 to 13 of said fatty acid is replaced with oxygen.

Abstract: Lipids obtained from blackcurrant seed are used for preventing proliferation and dissemination of cancerous metastases in patients.

Abstract: Novel spergualin-related compounds represented by the general formula (I): ##STR1## wherein X represents --(CH.sub.2).sub.1-5 -- or a phenylene group which may be substituted; m represents 0, 1 or 2; n represents 1 or 2; and R.sub.1 represents --(CH.sub.2).sub.1-3 --COOH, and pharmacologically acceptable salts thereof, possess an immunopotentiating activity, and are expected to be useful as immunopotentiators applicable to warm blooded animals.

Abstract: To improve the absorption of actve ingredients, which are not adequately bio-available on oral administration, an oral lipid medicinal composition is formed by combining a semi-solid, lipophilic component with a solid, water-soluble component. The semi-solid component is a homogeneous lipid mixture that exists as a hard fat with thermally reversible fat/liquid melting property, at least 95% of which is present in the liquid aggregate state below the body temperature of 37.degree. C. and comprises monoacyl-, diacyl-, and triacylglycerides of saturated vegetable fatty acids with chain lengths ranging from 6 to 18 carbon atoms, preferably comprising a mixture of 40 to 60% monoacyl- and diacylglycerides and 40 to 60% triacylglycerides, in which the active ingredients are either dissolved, suspended or emulsified.

Abstract: A composition of matter which consists of (a) from about 13.0 to about 27.5% by weight of at least one compound selected from the group consisting of linolenic acid and derivatives thereof, calculated as the free acid, said derivatives of linolenic acid being both physiologically hydrolyzable and pharmacologically acceptable, and (b) about 87.0 to about 72.5% by weight of at least one compound selected from the group consisting of linoleic acid and derivatives thereof, calculated as the free acid, said derivatives of linoleic acid being both physiologically hydrolyzable and pharmacologically acceptable, is utilized e.g. as a pharmaceutical formulation or nutritional composition, in absence of an oily carrier or diluent which comprises at least one member of the group consisting of C.sub.

Abstract: A gustatory stimulant composition for beetles of the sub-family Galerucinae comprising a dried and powdered Cucurbitaceae plant material, a lubricant, and an adherent, and a method of making the composition are disclosed. Methods for enhancing the effectiveness of an adulticide used against galerucinid beetles, for controlling a beetle population, and for stimulating the feeding of a beetle population with the composition of this invention are also disclosed.

Abstract: The use of one or more of the 6-desaturated or higher EFAs of each of the n-6 and n-3 series for the manufacture of a medicament for use in the treatment of post-viral fatigue syndrome (otherwise known as myalgic encephalomyelitis (ME)).

Abstract: A method for increasing the number of live births to a female animal by feeding the female animal beginning at least one week before the expected time of birth of the female animal's offspring, an edible flaxseed composition comprising ground flaxseed. This ground flaxseed composition can be admixed with a suitable animal feed. Zinc and/or vitamin B-6 can be included in the composition. An animal feed blend comprising an animal feed and a stable dry edible flaxseed composition comprising ground raw flaxseed.

Abstract: Some polyunsaturated acids (ximeninic acid, .gamma.-homo-linolenic acid, eicosapentaenoic acid), suitably formulated and administered by the topical route, possibly in form of glicerids or of complexes with phospholipids, have vasokinetic and vasodilative properties.

Abstract: This invention describes the use of a hydroxyoctadecadienic acid, its acid oxidized to keto form or the ester derivatives of the acids, where the ester derivatives are low esters with 1 to 4 carbon atoms for the preparation of a pharmaceutical for treatment of breast carcinomas or benign prostatic hyperplasia. In particular, those compounds are suitable in which the double bonds and the hydroxy group or the oxo group are present on the carbon atoms at positions 9 to 13.

Abstract: A method is provided for the treatment of hypolipaemic conditions and for reducing the concentration of cholesterol and triglycerides in the blood of mammals. The method comprises administering to a mammal an effective amount of non-.beta.-oxidizable fatty acid analogue of the formula Alkyl-X-CH.sub.2 COOR where the alkyl group is a saturated or unsaturated hydrocarbon chain of 8 to 22 carbon atoms, where X represents an oxygen atom, a sulfur atom, a sulfoxide (SO) or sulfone (SO.sub.2) group and where R is a hydrogen atom or an alkyl group of 1 to 4 carbon atoms. Pharmaceutical compositions are also provided.

Abstract: Preventive as well as therapeutic treatment to alleviate cosmetic conditions and symptoms of dermatologic disorders with amphoteric compositions containing alpha hydroxyacids, alpha ketoacids, related compounds or polymeric forms of hydroxyacids is disclosed. The cosmetic conditions and the dermatologic disorders in which the amphoteric compositions and the polymeric compounds may be useful include dry skin, dandruff, acne, keratoses, psoriasis, eczema, pruritus, age spots, lentigines, melasmas, wrinkles, warts, blemished skin, hyperpigmented skin, kyperkeratotic skin, inflammatory dermatoses, skin changes associated with aging, and skin requiring cleansers.

Abstract: A process for preparing an immunogenic conjugate of a nitroaromatic compound and a carrier comprises colavently bonding the nitroaromatic compound to the carrier in an essentially oxygen-free atmosphere and isolating the conjugate from the reaction mixture. The conjugate may be used to raise antibodies specific to the nitroaromatic hapten. The antibodies may be used to determine the presence of hypoxic tissue in living matter by treating the living matter with a nitroaromatic compound and subsequently testing suspected tissue to determine if there is binding of the antibody to tissue. By use of appropriate markers, bound antibodies can be determined to indicate the presence of hypoxic tissue due to the unique reaction of nitroaromatic compounds with hypoxic tissue.

Abstract: Pharmaceutical compositions and their preparation which contain dihydrolipoic acid or its pharmaceutically acceptable salts as active substance. The pharmaceutical compositions have a cytoprotective effect and are suitable for combatting pain and inflammatory disorders.

Abstract: Nuclear magnetic resonance (NMR) imaging of body organs and tissues is enhanced by administering to a living animal body a substantially nontoxic paramagnetic image altering agent comprised of a composition containing a chelate of a paramagnetic element, such as manganese, gadolinium or iron, carried by a liposome. The chelate is carried by or within the external surface of the liposome in such a manner that after arrival at or delivery to the desired organ or tissue site, the paramagnetic image altering agent is released in a diagnostically useful fashion.

Abstract: A method for measuring more accurately Fatty Acids and Essential Fatty Acid (EFA) Deficiencies (EFAD). The invention includes a disease diagnostic method for the diagnosis of lipid and fatty acid biochemical abnormalities found through the analysis of tissues of a test subject, deriving indices of lipid and fatty acid biochemical status, and analytically comparing patterns or domains obtained from indices of a subject with similar indices derived from tissues of subjects with normal and abnormal biochemistry, for the purposes of diagnosing abnormalities. A specific mixture of nutrients (test mixture), prepared according to this invention, is given to a test subject to modify the tissue composition of said test subject in order to verify or modify a diagnosis, including mixtures of w3 and w6 fatty acids. Another specific mixture of mixture of nutrients (treatment mixture), prepared according to this invention, is given to a test subject to correct lipid and fatty acid abnormalities found in said test subject.

Abstract: A method of inhibiting viruses by treatment with oxy- and thio-substituted fatty acid analog substrates of myristoylating enzymes is disclosed. These fatty acid analogs contain an oxygen or sulfur in place of a methylene group in a carbon position from 4 to 13 in the fatty acid chain of a C.sub.13 -C.sub.14 fatty acid or alkyl ester thereof.

Abstract: A stable dry edible flax seed composition comprising ground raw flax seed. An animal feed blend comprising: (1) animal feed, and (2) the above-described flax seed composition. A method for improving the general health and appearance of animals, increasing Omega-3 content of animal tissue and decreasing the cholesterol content of animal tissue comprising administering orally to a subject a biologically effective amount of the above-described flax seed composition. A method for improving the general health and appearnce of human beings and Omega-3 content of human being tissue comprising administering orally to a human being a biologically effective amount of the above-described flax seed composition. A method for producing the above-described stable dry edible flax seed composition comprising grinding raw flax seed at a temperature of from about 160.degree. F. to just above freezing. The flax seed composition can additionally comprise zinc and/or vitamin B-6.

Abstract: A paramagnetic oil emulsion for enteric administration composed of about 5 to about 30 volume percent oil and about 70 to about 95 volume percent aqueous-based paramagnetic carrier, the aqueous-based paramagnetic carrier having a magnetic resonance contrast effective and less than a toxic amount of at least one water-soluble paramagnetic agent. The paramagetic oil emulsion provides high intensity magnetic resonance signals in the gastro-intestional tract for MRI evaluation of the abdomen and pelvis.

Abstract: Licidal compositions for human use, comprising as active ingredient a comnd of the formulaR--COOH Iwherein R is a straight or branched C.sub.8 -C.sub.12 alkyl radical, a straight or branched C.sub.8 -C.sub.12 alkenyl radical or a substituted vinyl cyclopropyl radical of formula ##STR1## wherein R.sub.1 and R.sub.2 may each be methyl, halogen or trifluoromethyl; together with a suitable carrier.

Abstract: Novel cosmetic compositions comprising a lipid derived from horny cells can enhance a moisture retention ability of the horny layer and are useful for remedy of dry skin. When the lipid is used in combination with surface active agents, the above effect is enhanced.The cosmetic compositions may take any preparations such as creams, milky lotions, beauty wash, rouges, foundations, hair tonics and the like.

Abstract: A moisture stable solid valproic acid formulation is provided. The formulation comprises:55 to 65 weight percent valproic acid,10 to 25 weight percent fillers,10 to 20 weight percent disintegrants,3 to 6 weight percent binders, and0.5 to 1.2 weight percent lubricantsA preferred formulation is:60 weight percent of valproic acid,20 weight percent of magnesium oxide,15 weight percent corn or potato starch,3 weight percent polyvinylpyrrolidone,1 weight percent sodium carboxymethylcellulose,0.8 weight percent magnesium stearate.The formulations are manufactured by mxing an alcohol solution of valproic acid with the fillers, drying and then milling the mixture, adding the disintegrants and wet granulating with at least a portion of the binder. The wet granulate is dried, sized and to it is added the lubricant and any remaining binder.The lubricated granulate can be compressed into tablets without a protective coating.

Abstract: This invention concerns anti-hypertensive compositions and a method of lowering blood pressure in mammals. The active component of the compositions is a compound of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are independently chosen from straight chain and branched chain C.sub.1 -C.sub.12 alkyl groups and benzyl, with the proviso that no branch occur on the alpha carbon atom of the alkyl groups; or R.sub.1 and R.sub.2 together with the nitrogen atom they are bonded to form a pyrrolidino, piperidino, piperazino or morpholino group, M.sup.+ is a pharmaceutically acceptable cation, wherein X is the valence of the cation.

Abstract: The invention is directed to a composition of skin disorders, such as cellulites or striae, comprisingan oily fraction of paraffinic oils,an emulsifier, predominantly consisting ofa) mono- and/or diglycerides of higher unsaturated natural fatty acids, andb) ethoxylated glycerides esterified with fatty acids,pancreas extract and/or thymus extract derived from pancreas and/or thymus tissue as such or from previously partially hydrolized pancreased and/or thymus tissue,stabilizer consisting of montmorillonites, the free oxygen sites of which have been covered with quaternary groups,a preservative consisting of esters of p-hydroxybenzoic acid and/or substituted imidazolidinyl urea derivatives, andwater.

Abstract: This invention relates to pharmaceutical compositions comprising anaerobe-selective antibacterial agents which are substituted or unsubstituted, 1,12-dodecanedioic peroxy acids, or their pharmaceutically-acceptable salts or esters. The pharmaceutical compositions of the present invention are especially suitable for oral administration in the form of mouth rinses and toothpastes. These anaerobe-selective antibacterial compositions are useful for treating or preventing anaerobic bacterial infections, especially diseases of the oral cavity, in humans or lower animals.The present invention further relates to a method for treating or preventing anaerobic bacterial infections such as acne, and especially diseases of the oral cavity such as gingivitis and periodontal disease, in humans or lower animals.

Abstract: Methods of preventing oxidation, quenching singlet oxygen and inhibiting mold growth in a product comprises adding to the product a safe and effective amount of an active form of CLA. Active forms of CLA include 9,11-octadecadoenoic acid, 10,12-octadecadienoic acid, active isomers thereof, non-toxic salts thereof; active esters; other active chemical derivatives thereof, and mixtures thereof. Simple methods of making the compositions and novel compositions are also disclosed.

Abstract: Cosmetic and dermatological compositions containing from 1% to 30% by weight of an oil extracted from pips of Ribes genus fruits containing at least 4% by weight of .gamma.-linolenic acid are provided. The oil is substantially free from waxes, odorous compounds, colorings and free fatty acids.

Abstract: Novel methods for increasing milk yields in lactating ruminants are disclosed wherein somatotropin and salts of long chain fatty acids are administered generally coextensive in time to the animals in amounts sufficient to increase the production of milk.

Abstract: The invention relates to a therapeutic composition containing, as the active principle, .alpha.-linolenic acid and an alcohol of vegetable origin, such as a tocopherol or sitosterol. Preferably, the composition contains other fatty acids and is an organic extract of plants, especially of the Resedaceae family.The invention also relates to the plant extracts as novel products.The therapeutic composition is especially useful as an antiinflammatory.

Abstract: Lipid of blackcurrant seed is employed for treating of lipoprotein disorders associated with cholesterol metabolism. Its administration to humans produces an increase of cholesterol of the high-density lipoproteins and a reduction of the cholesterol of the low-density lipoproteins.

Abstract: Cosmetological or dermatological compositions for skin care, principally comprising a mixture comprising:(A) an extract of Silybum marianum fruits rich in Silymarine referred to as "Absolute Hawthorn",(B) one or more essential polyunsaturated fatty acids containing 18-22 atoms of carbon having only:either in the free form (1),or in the form of salts of an alkaline metal or ammonium (2),or in the form of triglycerides (3),or in the form of a mixture constituted by two of the three forms (1), (2), and (3), or by the three forms (1), (2), and (3).

Abstract: This invention is directed to antiviral and antibacterial activity of fatty acids and monoglycerides. More particularly, this invention is directed to the inactivation of enveloped viruses and the killing of cells by fatty acids and monoglycerides. The invention is also directed to an antiviral and/or antibacterial pharmaceutical composition consisting essentially of inert pharmaceutical carrier and an effective amount of one or more compounds selected from the group consisting of fatty acids and monoglycerides thereof.

Abstract: Anti-anal leakage agents are used in combination with liquid polyol fatty acid polyesters to provide pharmaceutical and food compositions for treating and/or preventing hypercholesterolemia while avoiding undesired anal leakage of the liquid polyesters.